[Clinical experiences with the new antidepressive agent ICI 58,834].
In an open study 17 patients with depressive disorders, 5 patients with unipolar affec. Only 9 patients completed the trial. The frequency of side-effects, especially nausea and vomiting was high, which will probably limit the clinical use of the drug. Of the sion NUD, were treated with a new potential antidepressant, ICI 58.834 (Vivalan). tive psychosis, 9 patients with reactio-neurotico-depressiva and 3 patients with deprespatients who completed the trial 1 was recovered and 4 were improved. Thus the antidepressive effect is dubious and must be tested in controlled studies.
D000284:Administration, Oral; D000328:Adult; D000368:Aged; D000928:Antidepressive Agents / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D003863:Depression / Q000188:drug therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009025:Morpholines / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*
D000928:Antidepressive Agents; D009025:Morpholines
Klinische Erfahrungen mit einem neuen Antidepressivum ICI 58.834